The launch of concentrated insulins and sodium–glucose cotransporter-2 inhibitors has been a boon for some patients with diabetes, with improved hemoglobin A1c levels and weight loss among the key benefits documented. But the agents also carry some risk: In the case of SGLT2 inhibitors, that includes elevated rates of bone fractures and decreased bone mineral density.
How should clinicians balance these factors when assessing the role of these newer treatment options in diabetes